Tanios S. Bekaii-Saab, MD, Mayo Clinic

Articles

Future Directions for mCRC Management

January 27th 2022

Gerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.

Sequencing Therapy for Relapsed mCRC

January 27th 2022

Gerald Prager, MD, leads the discussion on sequencing strategies for patients with relapsed mCRC, including those not previously treated with anti-EGFR inhibitors.

Management of Relapsed mCRC

January 27th 2022

Gerald Prager, MD, and Chiara Cremolini, MD, PhD, share their approach to managing the case of a 72-year-old man with mCRC disease progression and provide insight on rechallenging patients with anti-EGFR regimens.

Dosing Strategies for Regorafenib for Patients With mCRC

January 27th 2022

Chiara Cremolini, MD, PhD, discusses dosing strategies and the optimal management of adverse events with regorafenib for patients with mCRC.

Treatment Options After Progression on Chemotherapy/Anti-EGFR Therapy for mCRC

January 27th 2022

Experts in gastrointestinal cancers explore treatment approaches, such as with regorafenib, in patients with mCRC who have progressed on chemotherapy/anti-EGFR therapy.

Role of Maintenance Therapy in Advanced CRC

January 27th 2022

Chiara Cremolini, MD, PhD; Gerald Prager, MD; and Tanios S. Bekaii-Saab, MD, share their approach to maintenance therapy, including with EGFR inhibitors, for the management of advanced CRC.

Using ICI Therapy in MSI-High mCRC

January 27th 2022

Chiara Cremolini, MD, PhD, leads the discussion on the advantage of treating MSI-high metastatic colorectal cancer with immune checkpoint inhibitors.

Selecting Frontline Therapy for Newly Diagnosed mCRC

January 27th 2022

Tanios S. Bekaii-Saab, MD, presents the case of a 65-year-old woman with stage IV adenocarcinoma of the rectum, and the panel reviews frontline treatment options for a patient with newly diagnosed mCRC.

Role of Genomic Testing in mCRC

November 30th 2021

Experts in gastrointestinal cancers review the role of genomic testing in metastatic colorectal cancer and its impact on informing treatment decisions.

Overview of Colorectal Cancer

November 30th 2021

Tanios S. Bekaii-Saab, MD, Gerald Prager, MD, and Chiara Cremolini, MD, PhD, provide insight on the treatment landscape and international screening guidelines of colorectal cancer.

Treatments for BRAF-Mutated mCRC

April 16th 2021

Considerations for treating BRAF-mutated metastatic colorectal cancer with the combination of a BRAF inhibitor plus anti-EGFR agent based on recently presented data.

Second-Line Treatment of mCRC: Rechallenging Therapy

April 16th 2021

The role of molecular assays, including liquid biopsies, in providing information on resistance mechanisms in metastatic colorectal cancer and the impact of testing results on decisions for rechallenging with a previous therapy.

Preferences for Second-Line Therapy for mCRC

April 9th 2021

Drs Cathy Eng and Joleen M. Hubbard explain how patients with metastatic colon cancer typically respond to initial treatment and describe the factors that impact second-line treatment decisions.

Maintenance Therapy for Metastatic CRC

April 9th 2021

Recommendations regarding the selection, initiation, and length of maintenance therapy to help manage cases of metastatic colon cancer.

Optimizing mCRC Treatment: Decision-Making With Patients

March 25th 2021

An overview of topics that oncologists should counsel patients on when working with them to select therapy to treat metastatic colon cancer.

Initial Strategies for Assessing and Treating mCRC

March 25th 2021

Experts in gastrointestinal oncology highlight their approaches to assessing patients with newly diagnosed metastatic colorectal cancer and explain the variables that factor into first-line treatment decisions.

Future of NTRK Fusions

May 21st 2020

Challenges for TRK Fusion–Targeting Agents

May 21st 2020

Acquired Resistance in TRK Fusion-Positive Cancers

May 21st 2020

Approaching Treatment for TRK Fusion–Positive Cancers

May 21st 2020